Increased levels of NF-ATc2 differentially regulate CD154 and IL-2 genes in T cells from patients with systemic lupus erythematosus

Journal of Immunology

Volumn 178, Issue 3, 2007, Pages 1960-1966

  Kyttaris, Vaslleios C ^a,b,c   Wang, Ying ^a,b   Juang, Yuang Taung ^a,b   Weinstein, Arthur ^c   Tsokos, George C ^a,b,d  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

^c WASHINGTON HOSPITAL CENTER   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCINEURIN; CD40 LIGAND; CYCLIC AMP RESPONSIVE ELEMENT MODULATOR; DAPSONE; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 2; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR NFAT;

ADULT; ARTICLE; BINDING AFFINITY; CELL NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE CONTROL; GENETIC TRANSCRIPTION; HUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DNA BINDING; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

EID: 33846518435     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.178.3.1960     Document Type: Article

References (32)

1. Tsokos, G. C., and D. T. Boumpas. 2001. Systemic lupus erythematosus. In Molecular Pathology of Autoimmunity. C. Bona, ed. Gordon and Breach, Harwood Academic Publishers, New York, p. 255.
2. Tsokos, G. C., M. P. Nambiar, K. Tenbrock, and Y. T. Juang. 2003. Rewiring the T-cell: signaling defects and novel prospects for the treatment of SLE. Trends Immunol. 24: 259-263.
3. Kyttaris, V. C., Y. T. Juang, and G. C. Tsokos. 2005. Immune cells and cytokines in systemic lupus erythematosus: an update. Curr. Opin. Rheumatol. 17: 518-522.
4. Linker-Israeli, M., A. C. Bakke, R. C. Kitridou, S. Gendler, S. Gillis, and D. A. Horwitz. 1983. Defective production of interleukin 1 and interleukin 2 in patients with systemic lupus erythematosus (SLE). J. Immunol. 130: 2651-2655.
5. Desai-Mehta, A., L. Lu, R. Ramsey-Goldman, and S. K. Datta. 1996. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J. Clin. Invest. 97: 2063-2073.
6. Klee, C. B., H. Ren, and X. Wang. 1998. Regulation of the calmodulin-stimulated protein phosphatase, calcineurin. J. Biol. Chem. 273: 13367-13370.
7. Clipstone, N. A., and G. R. Crabtree. 1992. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature 357: 695-697.
8. 2+/calcineurin-NFAT-rnediated signaling. Mol. Cells 18: 1-9.
9. Macian, F. 2005. NFAT proteins: key regulators of T-cell development and function. Nat. Rev. Immunol. 5: 472-484.
10. Cron, R. Q., S. J. Bort, Y. Wang, M. W. Brunvand, and D. B. Lewis. 1999. T cell priming enhances IL-4 gene expression by increasing nuclear factor of activated T cells. J. Immunol. 162: 860-870.
11. Vassilopoulos, D., B. Kovacs, and G. C. Tsokos. 1995. TCR/CD3 complex-mediated signal transduction pathway in T cells and T cell lines from patients with systemic lupus erythematosus. J. Immunol. 155: 2269-2281.
12. Bombardier, C., D. D. Gladman, M. B. Urowitz, D. Caron, and C. H. Chang. 1992. Derivation of the SLEDAI: a disease activity index for lupus patients: The Committee on Prognosis Studies in SLE. Arthritis Rheum. 35: 630-640.
13. Tolnay, M., L. Baranyi, and G. C. Tsokos. 2000. Heterogeneous nuclear ribonucleoprotein DO contains transactivator and DNA-binding domains. Biochem. J. 348: 151-158.
14. Batiuk, T. D., L. Kung, and P. F. Halloran. 1997. Evidence that calcineurin is rate-limiting for primary human lymphocyte activation. J. Clin. Invest. 100: 1894-1901.
15. Shaw, K. T., A. M. Ho, A. Raghavan, J. Kim, J. Jain, J. Park, S. Sharma, A. Rao, and P. G. Hogan. 1995. Immunosuppressive drugs prevent a rapid dephosphorylation of transcription factor NFAT1 in stimulated immune cells. Proc. Natl. Acad. Sci. USA 92: 11205-11209.
16. + cells: downregulation upon myeloid differentiation. J. Leukocyte Biol. 76: 1057-1065.
17. Clipstone, N. A., and G. R. Crabtree. 1993. Calcineurin is a key signaling enzyme in T lymphocyte activation and the target of the immunosuppressive drugs cyclosporin A and FK506. Ann. NY Acad. Sci. 696: 20-30.
18. Solomou, E. E., Y. T. Juang, M. F. Gourley, G. M. Kammer, and G. C. Tsokos. 2001. Molecular basis of deficient IL-2 production in T cells from patients with systemic lupus erythematosus. J. Immunol. 166: 4216-4222.
19. Tenbrock, K., Y. T. Juang, M. F. Gourley, M. P. Nambiar, and G. C. Tsokos. 2002. Antisense cyclic adenosine 5′-monophosphate response element modulator up-regulates IL-2 in T cells from patients with systemic lupus erythematosus. J. Immunol. 169: 4147-4152.
20. Kyttaris, V. C., Y. T. Juang, K. Tenbrock, A. Weinstein, and G. C. Tsokos. 2004. Cyclic adenosine 5′-monophosphate response element modulator is responsible for the decreased expression of c-fos and activator protein-1 binding in T cells from patients with systemic lupus erythematosus. J. Immunol. 173: 3557-3563.
21. Herndon, T. M., Y. T. Juang, E. E. Solomou, S. W. Rothwell, M. F. Gourley, and G. C. Tsokos. 2002. Direct transfer of p65 into T lymphocytes from systemic lupus erythematosus patients leads to increased levels of interleukin-2 promoter activity. Clin. Immunol. 103: 145-153.
22. Koshy, M,, D. Berger, and M. K. Crow. 1996. Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J. Clin. Invest. 98: 826-837.
23. Yi, Y., M. McNerney, and S. K. Datta. 2000. Regulatory defects in Cb1 and mitogen-activated protein kinase (extracellular signal-related kinase) pathways cause persistent hyperexpression of CD40 ligand in human lupus T cells. J. Immunol. 165: 6627-6634.
24. Katsiari, C. G., S. N. Liossis, A. M. Dimopoulos, D. V. Charalambopoulo, M. Mavrikakis, and P. P. Sfikakis. 2002. CD40L overexpression on T cells and monocytes from patients with systemic lupus erythematosus is resistant to calcineurin inhibition. Lupus 11: 370-378.
25. Boumpas, D. T., R. Furie, S. Manzi, G. G. Illei, D. J. Wallace, J. E. Balow, and A. Vaishnaw. 2003. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum. 48: 719-727.
26. Grammer, A. C., R. Slota, R. Fischer, H. Gur, H. Girschick, C. Yarboro, G. G. Illei, and P. E. Lipsky. 2003. Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. J. Clin. Invest. 112: 1506-1520.
27. Iliopoulos, A. G., and G. C. Tsokos. 1996. Immunopathogenesis and spectrum of infections in systemic lupus erythematosus. Semin. Arthritis Rheum. 25: 318-336.
28. Refaeli, Y., L. Van Parijs, C. A. London, J. Tschopp, and A. K. Abbas. 1998. Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. Immunity 8: 615-623.
29. Miyara, M., Z. Amoura, C. Parizot, C. Badoual, K. Dorgham, S. Trad, D. Nochy, P. Debre, J. C. Piette, and G. Gorochov. 2005. Global natural regulatory T cell depletion in active systemic lupus erythematosus. J. Immunol. 175: 8392-8400.
30. Macian, F., C. Lopez-Rodriguez, and A. Rao. 2001. Partners in transcription: NFAT and AP-1. Oncogene 20: 2476-2489.
31. Cron, R. Q., R. Bandyopadhyay, A. Genin, M. Brunner, G. J. Kersh, J. Yin, T. H. Finkel, and M. K. Crow. 2006. Early growth response-1 is required for CD154 transcription. J. Immunol. 176: 811-818.
32. Juang, Y. T., Y. Wang, E. E. Solomou, Y. Li, C. Mawrin, K. Tenbrock, V. C. Kyttaris, and G. C. Tsokos. 2005. Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV. J. Clin. Invest. 115: 996-1005.